Dr. Philip Marcus, Chief, Division of Pulmonary Medicine at St. Francis Hospital, Roslyn, NY, says:
"The challenge for physicians who treat patients with asthma is to provide the best possible control with the lowest level of medication. Exhaled nitric oxide (eNO) provides an accurate measurement of airway inflammation which enables a more targeted corticosteroid prescription. This empowers physicians to decide the right treatment regimen for the right patient. In addition to Asthma Control Test (ACT) and pulmonary function testing, eNO appears to add another dimension in treating asthma and improving overall asthma control."
About Apieron
Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use, non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes like eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.
| SOURCE Apieron Inc. Copyright©2008 PR Newswire. All rights reserved |